Cytoguide Overview

  • Founded
  • 2007
  • Status
  • Acquired/​Merged
  • Latest Deal Type
  • M&A

Cytoguide General Information


Developer of combined drugs that target receptors on cells in pathological tissues. The company offers drugs that are aimed to improve the treatment of onocyte and macrophage-related diseases including autoimmune disease, leukemia and other infectious diseases.

Contact Information

Ownership Status
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Other Pharmaceuticals and Biotechnology
Primary Office
  • INCUBA Science Park
  • Gustav Wieds Vej 10
  • 8200 Aarhus
  • Denmark
+45 86 00 00 00
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Cytoguide Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Merger/Acquisition 01-Oct-2013 00.000 Completed Generating Revenue
4. Early Stage VC 08-Dec-2010 00.000 Completed Startup
3. Early Stage VC 02-Jun-2009 00.000 Completed Startup
2. Early Stage VC 28-Nov-2008 $2.39M $2.68M Completed Startup
1. Seed Round 01-Nov-2007 $287K $287K Completed Startup
To view Cytoguide’s complete valuation and funding history, request access »

Cytoguide Executive Team (2)

Name Title Board Seat Contact Info
Søren Moestrup Ph.D Chief Scientific Officer & Co-Founder
You’re viewing 1 of 2 executive team members. Get the full list »

Cytoguide Former Investors (4)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Capnova Venture Capital Minority 000 0000 000000 0
Karolinska Development Venture Capital Minority 000 0000 000000 0
Lund University Bioscience Venture Capital Minority 000 0000 000000 0
Novo Holdings Venture Capital Minority 000 0000 000000 0
To view Cytoguide’s complete investors history, request access »